

					

						November 30, 2017 - By Nellie Frank
 Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) had an increase of 22.4% in short interest. ACRX’s SI was 7.09M shares in November as released by FINRA. Its up 22.4% from 5.80 million shares previously. With 1.98M avg volume, 4 days are for Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX)’s short sellers to cover ACRX’s short positions. The SI to Acelrx Pharmaceuticals Incorporated’s float is 26.59%. The stock increased 1.16% or $0.025 during the last trading session, reaching $2.175. About 470,310 shares traded. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has declined 14.24% since November 30, 2016 and is downtrending. It has underperformed by 30.94% the S&P500.Hills Bank & Trust Company increased Us Bancorp New (USB) stake by 136.42% reported in 2017Q2 SEC filing. Hills Bank & Trust Company acquired 52,447 shares as Us Bancorp New (USB)’s stock declined 6.89%. The Hills Bank & Trust Company holds 90,893 shares with $4.72M value, up from 38,446 last quarter. Us Bancorp New now has $91.52 billion valuation. The stock increased 0.71% or $0.39 during the last trading session, reaching $55.15. About 8.43 million shares traded or 53.30% up from the average. U.S. Bancorp (NYSE:USB) has risen 23.07% since November 30, 2016 and is uptrending. It has outperformed by 6.37% the S&P500.Investors sentiment decreased to 0.75 in 2017 Q2. Its down 0.25, from 1 in 2017Q1. It worsened, as 17 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 11 funds opened positions while 13 raised stakes. 10.56 million shares or 22.04% less from 13.55 million shares in 2017Q1 were reported. Element Mngmt Lc reported 0.06% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Tower Research Ltd Limited Liability Company (Trc) invested 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Bluecrest Cap Mgmt Ltd invested in 0% or 12,866 shares. Perceptive Advsrs Ltd Liability invested in 3.73 million shares. Barclays Pcl stated it has 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Raymond James Assoc accumulated 45,000 shares or 0% of the stock. Drw Llc holds 0% or 10,000 shares. 49,761 were accumulated by Grt Cap Ptnrs Llc. 1.36M were reported by Vanguard Group Inc. Wells Fargo Com Mn reported 26,717 shares. Ing Groep Nv reported 39,000 shares stake. 14,964 are held by Bancshares Of America Corporation De. Salem Inv Counselors Inc invested in 3,435 shares or 0% of the stock. Cornerstone Inc holds 30,000 shares. Millennium Mngmt Limited holds 473,218 shares or 0% of its portfolio.Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 20 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, July 14 by Jefferies. On Wednesday, September 2 the stock rating was initiated by H.C. Wainwright with “Buy”. The firm has “Buy” rating by TH Capital given on Thursday, September 15. The rating was maintained by Jefferies with “Hold” on Tuesday, November 14. The firm has “Buy” rating given on Tuesday, May 3 by H.C. Wainwright. The firm earned “Buy” rating on Friday, May 6 by Seaport Global. The firm earned “Buy” rating on Friday, August 4 by H.C. Wainwright. The rating was maintained by RBC Capital Markets on Friday, August 25 with “Buy”. TH Capital maintained the stock with “Buy” rating in Monday, October 5 report. As per Thursday, October 12, the company rating was maintained by Piper Jaffray.AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $109.49 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

		var data = "63557954";
		document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="1262194147"></ins>')
	
(adsbygoogle = window.adsbygoogle || []).push({});